COMMUNIQUÉS West-GlobeNewswire
-
ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
28/10/2025 -
R1 Welcomes Estelle Barnes to Lead Enterprise Customer Engagement and Partnerships
28/10/2025 -
AssistRx Named a Winner of the Orlando Sentinel Media Group’s Central Florida Top Workplaces 2025 Award
28/10/2025 -
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
28/10/2025 -
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
28/10/2025 -
Glucotrack, Inc. Reminds Shareholders to Vote
28/10/2025 -
STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements
28/10/2025 -
Targeted Genomics Launches CeliacDx Consumer-Initiated Testing Service
28/10/2025 -
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
28/10/2025 -
Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors
28/10/2025 -
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
28/10/2025 -
Cidara Therapeutics to Participate in November Investor Conferences
28/10/2025 -
Soleno Therapeutics to Participate in Upcoming November Conferences
28/10/2025 -
BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025
28/10/2025 -
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
28/10/2025 -
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
28/10/2025 -
Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
28/10/2025 -
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
28/10/2025 -
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study
28/10/2025
Pages